Anticoagulation and Thrombolysis.
Publication/Presentation Date
12-1-2026
Abstract
Pulmonary embolism is a life-threatening condition requiring prompt anticoagulation to prevent clot propagation and recurrence. Risk stratification guides therapy, with systemic thrombolysis reserved for high-risk patients and selected intermediate-high risk cases due to significant bleeding risk. Direct oral anticoagulants are preferred for most low and intermediate-low risk patients, while low-molecular-weight heparin and unfractionated heparin remain critical for higher- risk or procedurally complex cases. Emerging strategies including low-dose thrombolysis, catheter-directed therapies, and the future use of Factor XI inhibitors may improve safety without compromising efficacy. Management of bleeding complications necessitates rapid intervention, reversal when available, and coordinated multidisciplinary care.
Volume
47
Issue
4
First Page
747
Last Page
757
ISSN
1557-8216
Published In/Presented At
Dong, M. Q., Ahuja, T., Merli, G., Rosovsky, R. P., Hunt, B. J., Horowitz, J. M., & West, F. M. (2026). Anticoagulation and Thrombolysis. Clinics in chest medicine, 47(4), 747–757. https://doi.org/10.1016/j.ccm.2026.07.007
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
42977381
Department(s)
Administration and Leadership
Document Type
Article